 phase II clinical trial carboplatin infusion high-risk acute nonlymphoblastic leukemia Carboplatin CBDCA second-generation platinum drug useful continuous infusion treatment refractory adult leukemia effectiveness continuous infusion CBDCA days patients secondary acute nonlymphocytic leukemia ANLL previous myelodysplastic syndrome treatment-associated ANLL ANLL patients first relapse refractory ANLL patients blastic phase chronic myelogenous leukemia BP-CML patients assessable response rate complete remissions CRs partial remissions PRs Median duration postchemotherapy neutropenia days range Therapy toxicity hematologic nondose-limiting prolonged neutropenia severe infections patients outpatients patients nausea vomiting symptomatic hypomagnesemia patient reversible ototoxicity substantial antileukemic activity unusual extrahematologic toxicity CBDCA effective second-line agent treatment ANLL first-line treatment regimens